OTCMKTS:KIADF Kiadis Pharma (KIADF) Stock Price, News & Analysis $6.41 0.00 (0.00%) As of 07/21/2021 Add Share Share Stock Analysis Stock AnalysisBuy This Stock About Kiadis Pharma Stock (OTCMKTS:KIADF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kiadis Pharma alerts:Sign Up Key Stats Today's Range$6.41▼$6.4150-Day Range$6.41▼$6.4152-Week Range$1.72▼$6.55VolumeN/AAverage Volume1,800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Kiadis Pharma N.V., a biopharmaceutical company, develops cell-based immunotherapy products in the field of blood building system. The company develops K-NK002 as an adjunctive immunotherapeutic, which is in Phase II clinical trials for blood cancer patients undergoing a haploidentical HSCT with the post-transplant cyclophosphamide (PTCy) protocol; and K-NK003, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia relapse/refractory (AML R/R). The company's preclinical stage product include K-NK00X, a NK-cell therapy candidate for the treatment of various solid tumors. It has a collaboration agreement with Harbour BioMed, Utrecht University, Erasmus Medical Center, and Viroclinics-DDL for the development of a combination of a monoclonal antibody and natural killer cells as a treatment for COVID-19. Kiadis Pharma N.V. was founded in 1997 and is headquartered in Amsterdam, the Netherlands. Read More Receive KIADF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiadis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address KIADF Stock News HeadlinesAscendis Pharma Announces FDA Approval Of YORVIPATH - Quick FactsAugust 14, 2024 | markets.businessinsider.comAgios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock SlidesAugust 1, 2024 | msn.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.August 2 at 2:00 AM | Crypto 101 Media (Ad)Kids and Taxes: 6 Tax Credits Parents Should Know AboutMay 26, 2024 | money.usnews.comLTRN Lantern Pharma Inc.April 7, 2024 | seekingalpha.comAlnylam PharmaceuticalsJanuary 31, 2024 | forbes.comTraveling With Little Kids Can Be Tough. The Right Gear Can Help.July 20, 2023 | nytimes.comThe Best Kids Luggage: 9 Picks for 2023June 27, 2023 | travel.usnews.comSee More Headlines KIADF Stock Analysis - Frequently Asked Questions How have KIADF shares performed this year? Kiadis Pharma's stock was trading at $6.41 at the beginning of the year. Since then, KIADF stock has increased by 0.0% and is now trading at $6.41. How do I buy shares of Kiadis Pharma? Shares of KIADF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorN/A Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:KIADF CIKN/A Webwww.kiadis.com Phone31 20 240 5250FaxN/AEmployees103Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (OTCMKTS:KIADF) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiadis Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiadis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.